pharmaphorum
SEPTEMBER 29, 2021
AbbVie has added a third drug to its arsenal in the crowded migraine market, getting FDA approval for Qulipta – its once-daily oral preventive therapy for episodic migraines. AbbVie acquired Qulipta in 2020 as part of its $63 billion takeover of Allergan, which also brought in Botox and Ubrelvy.
The Pharma Data
MARCH 30, 2021
2] – The atogepant application demonstrates AbbVie’s longstanding commitment to providing multiple migraine treatment options, including BOTOX® (onabotulinumtoxinA), a preventive treatment for those with chronic migraine, and UBRELVY® (ubrogepant), an acute treatment for adults with migraine. IMPORTANT SAFETY INFORMATION.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 2, 2020
Food and Drug Administration, Gover said he believes there is a “clear path” to the submission of a New Drug Application as soon as 2021. There are a few medications approved to treat spasticity, including the generic baclofen and Botox. Now is the ideal time to develop nabiximols in the U.S. It also forced the U.S.
pharmaphorum
NOVEMBER 4, 2020
The HER-MES trial found that Aimovig (erenumab) was more effective at preventing migraine attacks and also better tolerated than topiramate, a generic epilepsy drug which is known to have side effects like sleepiness, dizziness, diarrhoea and nausea. Novartis and Amgen are however locked in a legal battle over marketing rights to the drug.
pharmaphorum
NOVEMBER 18, 2020
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.
pharmaphorum
NOVEMBER 18, 2020
UK cost-effectiveness agency NICE has said that Eli Lilly’s Emgality can be made available through the NHS for migraine prevention, the second drug in the CGRP inhibitor class to achieve that milestone. Aimovig is said to be the most prescribed anti-CGRP drug worldwide with more than 480,000 patients prescribed the drug worldwide.
pharmaphorum
MARCH 2, 2022
The total value of the deal could rise to $1 billion, dependent on whether Syndesi’s SV2A drugs – headed by early-stage clinical candidate SDI-118 – progress in development and reach the market.
Expert insights. Personalized for you.
52 
Let's personalize your content